Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06344247
Other study ID # IIT-2023-0253
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 1, 2023
Est. completion date December 1, 2025

Study information

Verified date March 2024
Source RenJi Hospital
Contact Qin Wang
Phone +8613621964604
Email qinwang_1975@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to exploring the changes in 24-hour urinary protein and renal function in obese patients with kidney disease after the application of sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon like peptide-1 receptor agonists (GLP-1RA). Eligible patients were randomly and non-blindly allocated to four groups in a 1:1:1:1 ratio.The first group is the optimized treatment group, and patients in this group maintain the maximum dose/maximum tolerated dose of RAS blocker therapy. The second group is the optimized treatment + SGLT2i group. Participants in this group are titrated to the target dose (10 mg qd) in combination with dapagliflozin on the basis of optimized treatment. The third group is the optimized treatment + GLP-1RA group. Participants in this group will be titrated to the target dose (1mg qw) in combination with semaglutide on the basis of optimized treatment. The last group is the optimized treatment + SGLT2i + GLP-1RA treatment group, that is, based on the optimized treatment, combined with dapagliflozin titrated to the target dose (10 mg qd) and semaglutide titrated to the target dose (1 mg qw).


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date December 1, 2025
Est. primary completion date September 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Agree to join this study and sign an informed consent form; 2. Age = 18 years old and<75 years old; 3. BMI = 25kg/m ² Or waist circumference = 85cm (male)/= 80cm (female) or waist to hip ratio = 0.9 (male)/= 0.85 (female); 4. Confirmed obesity related kidney disease through renal biopsy within six months; 5. Have received optimized treatment with RAS blockers and/or MRA for at least 3 months; Exclusion Criteria: 1. Diagnosed as secondary obesity, such as hypothyroidism, Cushing's syndrome, polycystic ovary syndrome, etc; 2. Severe renal insufficiency (renal function eGFR<25 ml/min/1.73m2); 3. There is acute kidney injury; Defined as: (1) An increase in blood creatinine of = 26.5 within 48 hours µ Mol/L; (2) Within 7 days, the increase in blood creatinine exceeds 1.5 times the baseline value or more; (3) Reduced urine output (<0.5 ml/kg/h) and lasting for more than 6 hours. 4. Symptoms of active reproductive and urinary system infections 5. Severe liver dysfunction (ALT/AST greater than 2.5 times the upper normal limit); 6. Severe cardiovascular and cerebrovascular diseases, rheumatic and immune diseases; 7. Serious metabolic diseases, such as diabetes ketoacidosis, hypertonic hyperglycemia, etc; 8. Late stage malignant tumors; 9. Have a known history of using drugs that affect glucose and lipid metabolism, such as glucocorticoids, antibiotics, anti anxiety or antidepressants, etc; 10. Severe bleeding tendency and inability to complete venous blood collection; 11. There are contraindications for MRI examination, such as patients with pacemakers, nerve stimulators, artificial metal heart valves, etc; Patients with claustrophobia; Epilepsy patients, etc. 12. Pregnant/lactating women;

Study Design


Intervention

Drug:
RAS inhibitors:Losartan®?/Valsartan®?
Losartan®?/Valsartan®? : maintain the maximum dose/maximum tolerated dose.
dapagliflozin:Forxiga®?
Forxiga®? : titrated to the target dose (10 mg qd).
simagliptin:Forxiga®?
Semaglutide®? : titrated to the target dose (1 mg qw).

Locations

Country Name City State
China Renji Hospital Affiliated to Shanghai JIAO TONG University school of medicine Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
RenJi Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of 24-hour urine protein quantification According to KDIGO 2021 glomerular disease management guidelines. ? Remission: proteinuria is reduced, and serum albumin is >30g/L. Renal function is stable. Complete remission (CR): proteinuria is significantly reduced, 24HUTP<0.3g/L, and serum albumin>30g/L. Renal function is stable. Partial response (PR): proteinuria decreases, 24HUTP decreases >50% from baseline and >0.3g/L. Serum albumin>30g/L. Renal function is stable.
? Invalid: proteinuria is not reduced compared with baseline, and serum albumin is <30g/L. Renal function is stable or declining.
?Relapse: After achieving CR or PR, proteinuria increases (24-hour urine protein quantification =3.5g/d) and serum albumin decreases, <30g/L. Renal function is stable or declining.
4?12?24?36?48 WEEK
Secondary Decline in glomerular filtration rate 4?12?24?36?48 WEEK
Secondary Changes in BMI Body mass index 4?12?24?36?48 WEEK
Secondary changes in fasting blood glucose 4?12?24?36?48 WEEK
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2